The integration of CRT pacemaker and cardiac resynchronization therapy defibrillator significantly reduced during the Covid-19 pandemic
The U.S. Cardiac Resynchronization Therapy Market was pegged at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, growing at a CAGR of 4.9% from 2020 to 2027. The presence of favorable reimbursement policies, rise in investments, increase in technological advancements, and a growth in sedentary lifestyle among the U.S. population makes way for the growth of the cardiac resynchronization therapy market in the U.S. In addition, U.S. healthcare spending grew 4.6% in 2019 (as compared to 2018), reaching $3.8 trillion or $11,582 per person is expected to assist in the market growth over the forecast period. Cardiac resynchronization therapy (CRT) also known as biventricular pacing or multisite ventricular pacing, is a type of treatment to help correct serious heart rhythm problems. It involves simultaneous pacing of the right ventricle (RV) and the left ventricle (LV). CRT devices assist heart beat efficiently and monitor heart condition, thereby the healt...